Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Portfolio Pulse from Lara Goldstein
Cybin (NYSE:CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD). The company has delivered the highest dose of the drug with no serious adverse events reported. Cybin is planning to scale its clinical program around CYB003, which is protected by a U.S. patent until 2041, to a multinational Phase 3 study in early 2024. The company is also anticipating a potential FDA “Breakthrough Therapy” designation in 2023’s last quarter. Additionally, Cybin's acquisition of Small Pharma (OTC:DMTTF) is expected to take place within the last quarter of 2023.
September 22, 2023 | 2:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin has completed enrollment in its Phase 2 study of CYB003 for MDD treatment. The company is also anticipating a potential FDA “Breakthrough Therapy” designation in 2023’s last quarter.
The completion of Phase 2 study and the potential FDA “Breakthrough Therapy” designation could positively impact Cybin's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Cybin's acquisition of Small Pharma is expected to take place within the last quarter of 2023.
The acquisition could potentially strengthen Small Pharma's position in the market and positively impact its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80